Monkeypox Stocks Round 2: Mpox Stocks

Since I last wrote to you with a list of potential investments that could benefit from the recent monkeypox outbreak, that outbreak has gotten even worse. And I’ve learned that the preferred term for what I called monkeypox stocks is actually mpox stocks. So, since I made a mistake and called them monkeypox stocks… and since the outbreak has now spread outside of Africa… I’ve got a fresh list of mpox stocks that are already seeing some BIG investor interest.

But first, a mea culpa: When last I addressed those monkeypox stocks (that are actually mpox stocks), I was under the misconception that the strain making the rounds was the less virulent one that usually clears up on its own. But unfortunately, it’s the much stronger, more contagious, more severe strain going around. And that’s got people worried because this one can be passed very easily from person to person. And it’s got a potential mortality rate as high as 25%.

What We Know

Before we get into our updated list of mpox stocks, let’s cover what we know about the virus. It’s the more severe version. We know that. And it’s part of the same family that causes smallpox. That might sound pretty bad, but it means that this virus responds to some of the vaccines we’ve already developed for smallpox. That’s why Bavarian Nordic (OTC: BVNRY) is doing so well as one of my original mpox stocks. Its smallpox vaccine is the preferred preventative.

There are two types — clade 1 and clade 2. Clade 1 is the more severe. But it looks like this is a variant of clade 1 that’s also more virulent (clade 1b). That means it spreads faster. Up until last week, cases had been confined to the African continent. But now, at least one case has officially been reported in Europe. So far, there are no reported cases of clade 1 or 1b in the U.S., however.

It’s estimated that about 10 million vaccine doses are needed to address the outbreak in Africa. That’s a lot of vaccine. And that’s just for Africa. But will Bavarian Nordic be the only vaccine maker? Or are there some others that could turn into profitable mpox stocks? Let’s take a look…

These Mpox Stocks Are Like Gambling

Last time, I gave you the company that manufactures the preferred vaccine for this version of mpox. It’s Bavarian Nordic and it’s likely to be one of the top mpox stocks. Shares are up about 45% the past month as investors have taken notice of its increased orders.

But there are other vaccine makers that could benefit from this outbreak. And even if they don’t, they’re likely to see some investor speculation drive up share prices all the same. So let’s take a look at the companies with no viable vaccine but with the experience needed to make one quickly. Those are likely to be some impressive mpox stocks, too.

• Mpox Stocks: Geovax Labs Inc. (NASDAQ: GOVX)

One of those companies with no viable vaccine but that’s likely to see a lot of investor interest anyway is Geovax Labs Inc. (NASDAQ: GOVX). Now, GOVX stock is already up over 200% this past month as speculators speculate on which company might make a miracle cure. But it could still rise further. You know as well as I do that mania has no limits. And we saw how high speculators pushed stocks during the pre-vaccine days of the COVID trade.

Shares just took a hit the other day because the company took advantage of high prices to sell some shares and raise some money. But that could be a good thing for investors looking for mpox stocks now. This could be just the dip to buy.

• Mpox Stocks: Virax Biolabs Group Ltd. (NASDAQ: VRAX)

Another company with no viable treatment or vaccine that could still make one and win big is Virax Biolabs Group Ltd. (NASDAQ: VRAX). Now, this is another that’s already getting bid up pretty high by speculators speculating that it’ll get something going and become one of the top mpox stocks.

Over the past month it’s up 380%. But it, too, is going through a pullback after that meteoric run. Will it bounce back and continue to run up the charts? I can’t say for sure, but investors have sure decided that this is one of the best mpox stocks to make a wager on.

• Mpox Stocks: ARCA biopharma Inc. (NASDAQ: ABIO)

Next up in the mpox stocks that aren’t really mpox stocks but could become mpox stocks (that’s what people are investing in with these), is another small biotech company called ARCA biopharma Inc. (NASDAQ: ABIO). It, too, is up outlandishly in the past month on mpox stocks speculation. And it has yet to pull back. But in a recent move, it jumped from under $1.50 to over $3 overnight. So you can probably wait for a dip on this one before you add it to your mpox stocks list. Gaps do always get closed.

• Mpox Stocks: Cingulate Inc. (NASDAQ: CING)

And finally, I’ve got one more gamble on mpox stocks for you. It’s another small biotechnology operation that’s got nothing to do with mpox. But investors are already betting it’ll become one of the top mpox stocks, sending shares up triple digits the past week alone. It’s called Cingulate Inc. (NASDAQ: CING). And this might sound crazy coming from me, but I think this is the best gamble of the bunch, as it was a $100 stock to start the year but you can pick it up today for about $12. That makes it one of the few speculative mpox stocks with a history of higher prices.

Mpox Stocks Speculation

Look. I’m being completely honest with this coverage here. These stocks are only mpox stocks because they might make a treatment or vaccine for mpox in the future. They don’t have one yet. And you need to keep that in mind when placing your bets. If you want a vaccine company that has a vaccine for your mpox stocks, you need to go back to Bavarian Nordic.

These are also all stocks that speculators have already driven up a good bit. But they’re not the only ones. The mpox stocks I shared today are holding onto those outlandish gains better than their peers that have already fallen back down. So there may be some substance to them. Or maybe not.

They’re a bet that each company will be able to get something to market before this outbreak is contained. If that happens quickly, the highest-flying mpox stocks are going to crash back to Earth. If this outbreak becomes an even more global issue, there’s more time for the gamble to work out.

Just remember that’s all these mpox stocks are. If they don’t have a vaccine right now… if they don’t offer a treatment right now… if they can’t help you kill mpox right now… they’re not really mpox stocks at all. They’re potential mpox stocks.

That’s my way of saying that if you want to gamble a little bit of money on one or some of them, go right ahead. Just don’t bet the whole farm on these mpox stocks, even if you’re betting on the big-name mpox stocks I called monkeypox stocks in my last list.

Diversification isn’t just a buzzword. It’s a smart move for your investments, too.

To your wealth,

Jason Williams

@TheReal_JayDubs

Angel Research on Youtube

After graduating Cum Laude in finance and economics, Jason designed and analyzed complex projects for the U.S. Army. He made the jump to the private sector as an investment banking analyst at Morgan Stanley, where he eventually led his own team responsible for billions of dollars in daily trading. Jason left Wall Street to found his own investment office and now shares the strategies he used and the network he built with you. Jason is the founder of Main Street Ventures, a pre-IPO investment newsletter; the founder of Future Giants, a nano cap investing service; and authors The Wealth Advisory income stock newsletter. He is also the managing editor of Wealth Daily. To learn more about Jason, click here.

Want to hear more from Jason? Sign up to receive emails directly from him ranging from market commentaries to opportunities that he has his eye on.